The content on this site is intended for healthcare professionals only
At a press conference at SABCS 2012, Prof Bose presents on an analysis of data from a series of studies documenting breast cancer genome sequencing has confirmed that HER2 mutations may be ideal targets for breast cancer treatment. Further, the majority of these mutations are activating mutations that drive breast cancer cell growth in tissue culture.
The conference report of this meeting is available to read for free in ecancermedicalscience.
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis
Low-cost detection and treatment strategies for breast cancer patients in LMICs
Choosing wisely in breast cancer
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Overview of the management of HER2-low breast cancer patients
